Volitionrx LTD

VolitionRx Limited filed an 8-K detailing the reduction of its authorized common stock and the approval of its 2026 Stock Incentive Plan following its annual stockholder meeting.

VolitionRx Limited announced the issuance of common stock to Lind Global Asset Management XII LLC to satisfy debt obligations under a convertible promissory note.

VolitionRx Limited has entered into a waiver agreement with Lind Global Asset Management XII LLC following a breach of its market capitalization covenant.

VolitionRx Limited announced that director Mickie Henshall will not stand for re-election at the 2026 Annual Meeting.

VolitionRx Limited reported a significant increase in first-quarter revenue to $1.0 million and a 3% reduction in operating loss, alongside progress in its diagnostic test development and commercialization efforts.

VolitionRx Limited has implemented a one-for-twenty reverse stock split of its common stock, effective April 28, 2026.

VolitionRx Limited reported a significant increase in revenues driven by product sales, but also a wider net loss due to increased operating expenses and non-cash accounting charges.

VolitionRx Limited reported a net loss of $17.2 million for the nine months ended September 30, 2025, while actively raising capital and expanding commercialization efforts for its diagnostic tests.

VolitionRx Limited filed an amended quarterly report to include previously omitted exhibits, notably increasing its 'Capital On Demand' sales agreement to $30 million.

VolitionRx Limited reported a reduced net loss for the first half of 2025, driven by lower operating expenses, while expanding its Nu.Q Vet Cancer Test to 16 countries and securing new financing.

VolitionRx enters into a securities purchase agreement with Lind Global Asset Management for $6.25 million in funding, issuing a convertible note and common stock purchase warrant.

VolitionRx Limited's Q3 2024 results show a significant increase in revenue driven by product sales, particularly the Nu.Q Vet Cancer Test, alongside a reduction in operating expenses.

VolitionRx Limited filed an amendment to its 2025 Annual Report to include required Part III information and updated Sarbanes-Oxley certifications.

VolitionRx Limited appoints Timothy Still as non-executive Chairman of the Board, detailing his responsibilities, compensation, and the company's commitment to indemnification and insurance.

VolitionRx's 2023 annual report highlights the company's transition towards commercialization of its Nu.Q technology, alongside continued research and development in epigenetics.

VolitionRx's Chief Commercial Officer, Gael Forterre, reported the disposition of 5,251 common shares for tax withholding related to restricted stock unit settlement.

VolitionRx's Secretary, Rodney Gerard Rootsaert, reported a disposition of shares to cover tax obligations related to restricted stock unit vesting.

VolitionRx Chief Scientific Officer Jacob Vincent Micallef reported a transaction involving the withholding of 5,310 common shares to cover tax obligations from restricted stock unit settlement.

A Form 4 filing details the withholding of 7,003 VolitionRx shares from officer Nicholas Plummer to cover tax obligations upon the settlement of 14,900 restricted stock units.

VolitionRx's Chief Commercial Officer, Gael Forterre, was awarded 149,000 restricted stock units as part of the company's 2024 Stock Incentive Plan, in lieu of cash compensation.

VolitionRx director Ethel Rubin was awarded 178,000 restricted stock units, effective February 26, 2026, in lieu of cash compensation.

VolitionRx Limited announced its 2026 Annual Meeting of Stockholders, scheduled for July 17, 2026, and proposed a significant reduction in authorized shares.

VolitionRx Limited calls a special meeting to approve significant share issuance to Lind Global Asset Management and a potential reverse stock split to address listing compliance and marketability.

VolitionRx Limited is holding its 2025 Annual Meeting of Stockholders on June 18, 2025, to vote on key proposals including the election of directors and an increase in authorized shares.

VolitionRx is holding its annual meeting to elect directors, ratify the auditor, approve executive compensation, increase authorized shares, and approve a new stock incentive plan.

VolitionRx Limited has filed a Form S-1 registration statement to register shares of common stock issuable upon the exercise of various outstanding warrants.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 8.72% in VolitionRx Ltd., holding 9,380,425 shares.

Armistice Capital, LLC and Steven Boyd have updated their beneficial ownership in VolitionRx Ltd., reporting a collective stake of 9.99% as of March 31, 2025.

Lagoda Investment Management, L.P. has increased its beneficial ownership in VolitionRX Ltd to 11.3% of common stock as of June 30, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a combined beneficial ownership of 9.99% of VolitionRx Ltd.'s common stock, totaling 9,804,352 shares, as of March 31, 2025.

Lagoda Investment Management, L.P. has filed an amended Schedule 13G, revealing a significant passive beneficial ownership of 10.56% in VolitionRX Ltd.

Armistice Capital, LLC and Steven Boyd have reported a combined beneficial ownership of 9.99% of VolitionRx Ltd.'s common stock as of December 31, 2024.